Research ArticleArticle
Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease HSP90 and the Androgen Receptor Levels and Inhibit Viability in Enzalutamide Resistant C4-2 Prostate Cancer Cells
Rayna Rosati, Bailing Chen, Mugdha Patki, Thomas McFall, Siyu Ou, Elisabeth Heath, Manohar Ratnam and Zhihui Qin
Molecular Pharmacology July 5, 2016, mol.116.103416; DOI: https://doi.org/10.1124/mol.116.103416
Rayna Rosati
1 Wayne State University/Karmanos Cancer Institute;
Bailing Chen
2 Wayne State University;
Mugdha Patki
3 Barbara Ann Karmanos Cancer Institute and Department of Oncology
Thomas McFall
1 Wayne State University/Karmanos Cancer Institute;
Siyu Ou
2 Wayne State University;
Elisabeth Heath
3 Barbara Ann Karmanos Cancer Institute and Department of Oncology
Manohar Ratnam
3 Barbara Ann Karmanos Cancer Institute and Department of Oncology
Zhihui Qin
2 Wayne State University;
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease HSP90 and the Androgen Receptor Levels and Inhibit Viability in Enzalutamide Resistant C4-2 Prostate Cancer Cells
Rayna Rosati, Bailing Chen, Mugdha Patki, Thomas McFall, Siyu Ou, Elisabeth Heath, Manohar Ratnam and Zhihui Qin
Molecular Pharmacology July 5, 2016, mol.116.103416; DOI: https://doi.org/10.1124/mol.116.103416
Research ArticleArticle
Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease HSP90 and the Androgen Receptor Levels and Inhibit Viability in Enzalutamide Resistant C4-2 Prostate Cancer Cells
Rayna Rosati, Bailing Chen, Mugdha Patki, Thomas McFall, Siyu Ou, Elisabeth Heath, Manohar Ratnam and Zhihui Qin
Molecular Pharmacology July 5, 2016, mol.116.103416; DOI: https://doi.org/10.1124/mol.116.103416
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement